Skip to main content

Gut Microbiota in a Viral Model of Multiple Sclerosis: Modulation and Pitfalls by Oral Antibiotic Treatment.

Publication ,  Journal Article
Ahmad, I; Omura, S; Khadka, S; Sato, F; Park, A-M; Rimal, S; Tsunoda, I
Published in: Cells
June 2025

Viral infections have been associated with multiple sclerosis (MS), an immune-mediated disease in the central nervous system (CNS). Since Theiler's murine encephalomyelitis virus (TMEV) can induce MS-like demyelination, TMEV infection is the most widely used viral model for MS. Although the precise pathophysiology is unknown, altered fecal bacterial populations were associated with distinct immune gene expressions in the CNS. We aimed to determine the role of gut microbiota in TMEV infection by administering an antibiotic cocktail in drinking water before (prophylactic administration) or after (therapeutic administration) TMEV infection. The antibiotic administration reduced total eubacteria, including the phyla Bacillota and Bacteroidota, but increased the phylum Pseudomonadata in feces. Prophylactic administration did not alter TMEV-induced inflammatory demyelination clinically or histologically, without changes in anti-viral IgG1/IgG2c levels or lymphoproliferative responses; therapeutic administration temporarily suppressed the neurological signs. Although antibiotic treatment had minimal effects on TMEV infection, adding metronidazole and ampicillin in drinking water substantially reduced water intake in the antibiotic group of mice, resulting in significant body weight loss. Since dehydration and stress could affect immune responses and gut microbiota, caution should be exercised when planning or evaluating the oral antibiotic cocktail treatment in experimental animals.

Duke Scholars

Published In

Cells

DOI

EISSN

2073-4409

ISSN

2073-4409

Publication Date

June 2025

Volume

14

Issue

12

Start / End Page

871

Related Subject Headings

  • Theilovirus
  • Multiple Sclerosis
  • Mice, Inbred C57BL
  • Mice
  • Gastrointestinal Microbiome
  • Female
  • Disease Models, Animal
  • Anti-Bacterial Agents
  • Animals
  • Administration, Oral
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Ahmad, I., Omura, S., Khadka, S., Sato, F., Park, A.-M., Rimal, S., & Tsunoda, I. (2025). Gut Microbiota in a Viral Model of Multiple Sclerosis: Modulation and Pitfalls by Oral Antibiotic Treatment. Cells, 14(12), 871. https://doi.org/10.3390/cells14120871
Ahmad, Ijaz, Seiichi Omura, Sundar Khadka, Fumitaka Sato, Ah-Mee Park, Sandesh Rimal, and Ikuo Tsunoda. “Gut Microbiota in a Viral Model of Multiple Sclerosis: Modulation and Pitfalls by Oral Antibiotic Treatment.Cells 14, no. 12 (June 2025): 871. https://doi.org/10.3390/cells14120871.
Ahmad I, Omura S, Khadka S, Sato F, Park A-M, Rimal S, et al. Gut Microbiota in a Viral Model of Multiple Sclerosis: Modulation and Pitfalls by Oral Antibiotic Treatment. Cells. 2025 Jun;14(12):871.
Ahmad, Ijaz, et al. “Gut Microbiota in a Viral Model of Multiple Sclerosis: Modulation and Pitfalls by Oral Antibiotic Treatment.Cells, vol. 14, no. 12, June 2025, p. 871. Epmc, doi:10.3390/cells14120871.
Ahmad I, Omura S, Khadka S, Sato F, Park A-M, Rimal S, Tsunoda I. Gut Microbiota in a Viral Model of Multiple Sclerosis: Modulation and Pitfalls by Oral Antibiotic Treatment. Cells. 2025 Jun;14(12):871.

Published In

Cells

DOI

EISSN

2073-4409

ISSN

2073-4409

Publication Date

June 2025

Volume

14

Issue

12

Start / End Page

871

Related Subject Headings

  • Theilovirus
  • Multiple Sclerosis
  • Mice, Inbred C57BL
  • Mice
  • Gastrointestinal Microbiome
  • Female
  • Disease Models, Animal
  • Anti-Bacterial Agents
  • Animals
  • Administration, Oral